Faster storage is en route to future high-end smartphones and other mobile devices, and it's coming in the form of UFS 5.0 chips based on the next-generation of Unified Flash Storage protocol.
The FDA has approved a new four-dose, single-patient-use KwikPen for Zepbound (tirzepatide), giving patients a full month of treatment in one device.
Lilly Larson could have quit gymnastics a long time ago. It would be understandable — she lives an hour away from the nearest gym. "Jamestown is an hour from where I live, but it was the only option ...
Beatrice Vos, Celine Halioua, Laura Gustafson, and Fabian Kausche recognized for leadership, innovation and mentorship ...
With all these teenagers competing for Team USA in snowboarding and freestyle skiing, what do they do for high school?
Labor force participation for women with small children continues to float above prepandemic levels, thanks to flexible work setups — and rising costs.
Taiwan’s PharmaEssentia has committed $46 million to build a Puerto Rico drug manufacturing facility to serve the U.S. market ...
When Mike Doustdar started as a summer employee making copies at Novo Nordisk—a teenager living in Austria after fleeing unrest in his home country of Iran at 12—he never imagined he would remain at ...
As the 2026 Winter Olympics get underway in Italy this week, Eli Lilly—a partner of both Team USA and the Milan Cortina Games as a whole—is rolling out a new corporate campaign inspired by the event.
Eli Lilly is rated SELL due to lofty valuation, despite extraordinary execution and recent market leadership in GLP-1 and obesity drugs. LLY's current $950B market cap implies sustained 25% annual ...
Eli Lilly posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. The ...
Eli Lilly said it will spend $3.5 billion to build a manufacturing plant in Pennsylvania's Lehigh Valley that will help make its next-generation obesity drugs. That includes a closely watched ...